Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies.

Nat Med · 2025 · PMC12092283 · PMID 40301559

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Felzartamab treatment for 20 weeks suppressed histologic ABMR and decreased MVI substantially, with 7 out of 11 patients achieving an MVI score of zero at week 24, and a nonsignificant trend toward stabilization of estimated glomerular filtration rate (eGFR) at week 52.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.